*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep American journal of physiology. Endocrinology and metabolism · preclinical | PMID 39679943 |
| 2025 | Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice Journal of Alzheimer's disease : JAD · preclinical | PMID 39610283 |
| 2023 | Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris Applied microbiology and biotechnology · preclinical | PMID 37261455 |
| 2023 | Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets Journal of developmental origins of health and disease · preclinical | PMID 37114757 |
| 2020 | Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep FASEB journal : official publication of the Federation of American Societies for Experimental Biology · preclinical | PMID 32573852 |
| 2010 | Detection of His-tagged Long-R³-IGF-I in a black market product Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · preclinical | PMID 20675162 |
| 1999 | Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers Domestic animal endocrinology · preclinical | PMID 10370861 |
| 1997 | The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I The American journal of physiology · preclinical | PMID 9252489 |
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1). Modified IGF-1 analogue with an Arg3 substitution and N-terminal extension that markedly reduces binding to IGF-binding proteins, prolonging activity. Potent anabolic/proliferative signalling via IGF-1R.
Commonly discussed uses: muscle-growth research (cell culture; supplied for laboratory use). The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: Modified IGF-1 analogue with an Arg3 substitution and N-terminal extension that markedly reduces binding to IGF-binding proteins, prolonging activity. Potent anabolic/proliferative signalling via IGF-1R.
Reported considerations: hypoglycaemia (potentially severe), theoretical: promotion of occult tumour growth, organ growth concerns with chronic use. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. WADA-prohibited. No established human therapeutic use; significant hypoglycaemia and theoretical oncogenic risk. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established safe human dose; anecdotal 20-50mcg unvalidated, high unknown safe ceiling — hypoglycaemia risk. Administration: subcutaneous/intramuscular (anecdotal, unvalidated). Half-life: ~20-30 hours (extended vs native IGF-1).
Australian status: Not ARTG-registered; research; WADA prohibited (S2). WADA-prohibited. No established human therapeutic use; significant hypoglycaemia and theoretical oncogenic risk. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined (acidic diluent typical); storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): used in anabolic protocols (anecdotal, high-risk). Stacking increases interaction/safety uncertainty.